We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Zynex Inc | NASDAQ:ZYXI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.77 | 11.05 | 11.77 | 5 | 12:00:00 |
ENGLEWOOD, Colo., March 6, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will postpone the release of its fourth quarter and full year financial results and conference call initially scheduled for Monday, March 6, 2023 at 4:15 p.m. ET.
The company will announce its fourth quarter and full year 2022 financial results and conference call schedule in a future press release to allow additional time to complete its year-end closing procedures.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufacturers, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com
Contact: Zynex, Inc. (800) 495-6670
Investor Relations Contact:
Gilmartin Group
Investor Relations Counsel
ir@zynex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-inc-to-postpone-fourth-quarter-and-full-year-2022-financial-results-release-and-conference-call-301763794.html
SOURCE Zynex
Copyright 2023 PR Newswire
1 Year Zynex Chart |
1 Month Zynex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions